## MOQC Excellence in Quality Certification



## **MOQC Excellence in Certification Measures 2024**

- A practice pursuing MEQC must meet the target for 80% or more of the certification measures, specified below.
- The data measurement period will be from Jan 1, 2024 through Oct 31, 2024.

Measure Number	Measure	Target
115	Use of a 4-drug combination of antiemetic agents in patients on high emetic risk chemotherapy	55%
111	GCSF (Granulocyte colony stimulating factor) administered to patients who received chemotherapy for non-curative intent (lower score = better)	10%
130	Beginning a new anti-cancer regimen within 14 days of death (lower score = better)	30%
114	NK1 receptor antagonist administered for low or moderate emetic risk cycle 1 chemotherapy (lower score = better)	10%
126c	Hospice enrollment more than 30 days before death	20%
129	Palliative care consultation more than 90 days before death	25%
101b	Tobacco cessation counseling for tobacco users once a year	75%
103	Designated advocate documented on a legally recognized document in the inpatient or outpatient medical record	20%
123	Days from debulking surgery to chemotherapy (Gynecologic Oncology only)	28 or less
116	Median opioid prescribing (measured as oxycodone tablets, equivalent) following surgical procedure (Gynecologic Oncology only)	9 pills or less

